PreveCeutical Medical Inc. (18H.F)
Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
As of 08:00AM CEST. Market open.
| Previous close | 0.0100 |
| Open | 0.0105 |
| Bid | 0.0105 x 0 |
| Ask | 0.0190 x 0 |
| Day's range | 0.0105 - 0.0105 |
| 52-week range | 0.0100 - 0.0275 |
| Volume | |
| Avg. volume | 4,275 |
| Market cap | 11.376M |
| Beta (5Y monthly) | 1.06 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
PREVECEUTICAL INITIATES PREPARATION OF PROOF-OF-CONCEPT PRECLINICAL STUDY FOR ITS DIABETES & OBESITY DUAL GENE THERAPY PROGRAM
PreveCeutical Medical Inc. (the "Company" or "PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), is pleased to announce that it has started preparations to accelerate completion of its preclinical dual gene therapy program using our developed and in vitro validated Smart-siRNA sequences, which when paired with our proprietary bioresponsive lipid-nanoparticulate delivery systems (US patent no. 11,566,044) effectively target the PTPN1 gene.
© 2024 Yahoo. All rights reserved.